Synergy Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The Company also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Type
Public
HQ
New York, US
Founded
1992
Size (employees)
116 (est)
Synergy Pharmaceuticals was founded in 1992 and is headquartered in New York, US
Report incorrect company information

Key People/Management at Synergy Pharmaceuticals

Pharm.D Troy Hamilton

Pharm.D Troy Hamilton

Director and Chief Executive Officer
Patrick H. Griffin M.D., FACP

Patrick H. Griffin M.D., FACP

Executive Vice President and Chief Medical Officer
Marino Garcia

Marino Garcia

Executive Vice President and Chief Strategy Officer
Gary Gemignani

Gary Gemignani

Executive Vice President and Chief Financial Officer
Chhaya Shah

Chhaya Shah

Senior Vice President, Manufacturing & Technical Operations
Dan Dunham J.D

Dan Dunham J.D

Senior Vice President and Chief Compliance Officer
Show more

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Avenue Suite 2012
Show all (1)
Report incorrect company information

Synergy Pharmaceuticals Financials and Metrics

Synergy Pharmaceuticals Financials

Synergy Pharmaceuticals's revenue was reported to be $16.82 m in FY, 2017
USD

Revenue (Q1, 2018)

8.6 m

Gross profit (Q1, 2018)

4.9 m

Gross profit margin (Q1, 2018), %

56.9%

Net income (Q1, 2018)

(36.1 m)

EBIT (Q1, 2018)

(38.7 m)

Market capitalization (23-May-2018)

394.8 m

Closing share price (23-May-2018)

1.6

Cash (31-Mar-2018)

98.7 m
Synergy Pharmaceuticals's current market capitalization is $394.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.8 m

Cost of goods sold

8.8 m

Gross profit

8 m

Gross profit Margin, %

48%
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

98 k2.3 m8.6 m

Cost of goods sold

1.8 m2.9 m3.7 m

Gross profit

(1.7 m)(576 k)4.9 m

Gross profit Margin, %

(1742%)(25%)57%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

18.1 m146.5 m61.7 m82.4 m137 m

Accounts Receivable

554 k6.5 m

Inventories

3.7 m3.8 m3.3 m5.6 m17.2 m

Current Assets

71.9 m200.2 m115.1 m88.9 m165.2 m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

12.1 m20.6 m12.8 m78.7 m61.7 m41.9 m84.2 m141.2 m109.1 m139.3 m82 m98.7 m

Accounts Receivable

6.3 m1.8 m7.4 m

Inventories

9.6 m11.9 m16.2 m

Current Assets

87.3 m76.2 m36.9 m182.3 m164 m143.1 m87.5 m145.5 m110.8 m163.3 m104 m131.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.1 m)(95.7 m)(117.5 m)(198.6 m)(224.3 m)

Depreciation and Amortization

56 k120 k163 k233 k165 k

Inventories

(2.2 m)(124 k)531 k(5.6 m)(11.6 m)

Accounts Payable

7.1 m316 k1.9 m11.5 m8.7 m
Quarterly
USDQ3, 2013Q1, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(13.5 m)(16.2 m)(23 m)(27.4 m)(61.1 m)(87.1 m)(59.9 m)(38.6 m)(40.2 m)(64.6 m)(36.1 m)

Depreciation and Amortization

67 k103 k48 k

Inventories

9.6 m1 m

Accounts Payable

15.2 m11.2 m(1.3 m)(1 m)13.6 m19 m15.8 m28.4 m(1 m)
USDY, 2018

Financial Leverage

-3.4 x
Show all financial metrics

Synergy Pharmaceuticals Operating Metrics

Synergy Pharmaceuticals's Patent Applications was reported to be 3 in FY, 2016.
FY, 2016

Patent Applications

3

Patents (US)

21

Patents (foreign)

8

Patents Pending

93
Show all operating metrics
Report incorrect company information